Review of Current Evidence and Comparison of Guidelines for ...

More documents

Recommendations

Info

EUR/03/5045931 page 52 Authors, year Mashkillejson A.L., et al., 1997 (8) Petrenko L..А., 1996 (9) Skripkin J.K., et al., 1998 (10) Loseva O.K., et al., 1998 (11) Akovbian V.A., et al., 1998 (12) Fedorova L.D., et al., 1998 [13] Chebotarev V.V., et al., 1999 [14] No. of patients Table 3. Results of the treatment of syphilis diseased patients with Benzatinpenicillin Distribution under diagnoses Results of the treatment Seroconversion Seroresistance Primary Secondary Latent Primary Secondary Latent Primary Secondary Latent Serological relapse Clinical relapse 366 127 156 83 100% 96% – – 346 129 143 74 100% 100% 100% – – 142 142 91.5% 8.5% – – 406 50 206 150 100% 92% 93.4% – 4.8% 4.1% 2.5% 0.28% 23 183 200 140 100% 99% 91.5% – 1% 8.5% 0.3% – 140 59 67 100% 100% – – – – 237 Is not present the data under diagnoses 97.5% 2.5% 0.84% 2.5%
EUR/03/5045931 ORIGINAL: ENGLISH UNEDITED E81699
Page 1 and 2:
Review of Current Evidence and Comp
Page 3 and 4:
CONTENTS Page Foreword ............
Page 5:
Foreword EUR/03/5045931 page i “C
Page 8 and 9: EUR/03/5045931 page 2 addition ther
Page 10 and 11: EUR/03/5045931 page 4 differences i
Page 12 and 13: EUR/03/5045931 page 6 The CDC guide
Page 14 and 15: EUR/03/5045931 page 8 United Kingdo
Page 16 and 17: EUR/03/5045931 page 10 reports of t
Page 18 and 19: EUR/03/5045931 page 12 Acknowledgem
Page 20 and 21: EUR/03/5045931 page 14 32. Schofer
Page 22 and 23: EUR/03/5045931 page 16 70. Mohr J,
Page 24 and 25: EUR/03/5045931 page 18 110. Onoda Y
Page 26 and 27: EUR/03/5045931 page 20 Table 2a Ear
Page 28 and 29: EUR/03/5045931 page 22 Table 3 Late
Page 30 and 31: EUR/03/5045931 page 24 Table 5 Preg
Page 32 and 33: EUR/03/5045931 page 26 Table 7 Evid
Page 34 and 35: EUR/03/5045931 page 28 Annex 1 GOH
Page 36 and 37: EUR/03/5045931 page 30 Annex 3 UK N
Page 38 and 39: EUR/03/5045931 page 32 Annex 5 AKOV
Page 40 and 41: EUR/03/5045931 page 34 The period 1
Page 42 and 43: EUR/03/5045931 page 36 Method 3 Tre
Page 44 and 45: EUR/03/5045931 page 38 is that inst
Page 46 and 47: EUR/03/5045931 page 40 started the
Page 48 and 49: EUR/03/5045931 page 42 Treatment of
Page 50 and 51: EUR/03/5045931 page 44 Method 3 In
Page 52 and 53: EUR/03/5045931 page 46 HIV-positive
Page 54 and 55: EUR/03/5045931 page 48 the latent s
Page 56 and 57: EUR/03/5045931 page 50 15. Order No
show all

Review of Current Evidence and Comparison of Guidelines for ...

Create successful ePaper yourself

Delete template?

Save as template?